SCHG — the Schwab U.S. Large-Cap Growth ETF — is flashing an unusual split signal this week: options positioning has shifted to its most bullish extreme in a year, even as short interest has quietly doubled in the past seven days.
The options story is the headline. The put/call ratio has collapsed to 0.27, nearly three standard deviations below its 20-day average of 0.39 — a reading that puts it close to the 52-week floor of 0.22. That tells you call demand is running far ahead of put buying right now. The shift is sharp: the PCR was sitting comfortably in the 0.39–0.42 range as recently as mid-July before breaking lower in the final two sessions of the week. Whether that reflects fresh conviction or simply expiry-related flow, the skew is now heavily one-directional.
Short interest tells a different story, and the contrast is worth naming directly. Shares short have doubled over the past week to roughly 4.3 million — a 100% seven-day increase — and are up 71% on the month. In absolute terms, this remains tiny for an ETF of SCHG's size: short interest is just 0.27% of float, well below any threshold where squeeze dynamics become relevant. The borrow market reflects that ease. Cost to borrow is 0.54%, less than half where it was in late June when it briefly touched above 1%. Availability is deep at around 1,074% of short interest — meaning there are more than ten shares available to lend for every one currently borrowed — and the 52-week minimum availability has never dropped below 508%. The lending market here is structurally loose, and the short-interest pickup reads more like routine ETF arbitrage or hedging activity than any directional conviction against U.S. large-cap growth.
The ORTEX short score of 29.5 confirms the picture: it has ticked up gradually from 26.4 a week ago, but at sub-30 it still ranks in the lower tier of the scoring range. That creep upward merits watching but is not alarming in isolation. The combined score sits almost identically at 29.5, suggesting no divergence between the short-specific and broader signal sets.
Price action on the week has been muted. SCHG slipped 0.9% over the past five sessions to close at $34.27, though it recovered 0.35% in Tuesday's session and remains up just over 1% on the month. Valuation data is stale and the fund carries no earnings calendar, so the traditional fundamental anchors are absent here. What the snapshot does show is a fund where the mechanical rebalancing — modest trims to mega-cap tech, marginal additions to lagging growth names — has proceeded without drama, and where the 0.08% expense ratio continues to attract cost-sensitive flows.
The setup to watch is whether the PCR holds near its 52-week low as July options expire, or snaps back toward the historical average around 0.39 — and whether the short-interest build, small as it is, continues on its current trajectory into August.
See the live data behind this article on ORTEX.
Open SCHG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
